Valeant Pharmaceuticals International Inc (VRX)

15.46
NYSE : Health Care
Prev Close 15.44
Day Low/High 15.35 / 15.89
52 Wk Low/High 13.77 / 119.87
Avg Volume 18.06M
Exchange NYSE
Shares Outstanding 347.67M
Market Cap 5.37B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cramer: Make a Deal or Face the Wheel

Cramer: Make a Deal or Face the Wheel

Give me a Trump stock! I want a Trump stock!

Questions Mount at Teva as Generics Head Quits Without Explanation

Questions Mount at Teva as Generics Head Quits Without Explanation

Siggi Olfasson is poised to step down as president and CEO of Teva's global generic medicines group by the end the first quarter of 2017.

Apple, Starbucks, Cisco: Doug Kass' Views

Apple, Starbucks, Cisco: Doug Kass' Views

Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'

Ranking the Activists for Proxy Season 2016

Ranking the Activists for Proxy Season 2016

We recount the successes and failures of the biggest names in the activism game.

SEC Discloses Correspondence Over Valeant's Accounting Practices

SEC Discloses Correspondence Over Valeant's Accounting Practices

The SEC has released correspondence between the agency and Valeant over concerns about its tax accounting and non-GAAP reporting measures.

Crude Surge Marches Dow to Near Record Close

Crude Surge Marches Dow to Near Record Close

Wall Street was torn in two with the energy sector marching the Dow Jones Industrial Average higher, while health care and tech weighed on the Nasdaq.

Dow Climbs as Crude Rally Lights Fire Under Energy Sector, S&P 500 Falls

Dow Climbs as Crude Rally Lights Fire Under Energy Sector, S&P 500 Falls

The Dow Jones Industrial Average leads markets on Wednesday as a rally in crude oil lights a fire under the energy sector.

How to Trade Wednesday's Most Active Stocks -- Chesapeake Energy, American Eagle, More

How to Trade Wednesday's Most Active Stocks -- Chesapeake Energy, American Eagle, More

Here's a technical look on how to trade some of the most active stocks on the market today.

Valeant and Tribune Media Rebounds Not in Sight

Valeant and Tribune Media Rebounds Not in Sight

Technical analysis does not yield positives for the pharmaceutical company, TV station owner or the nuclear power industry.

Midday Report: Valeant Sinks as Deal Talks Break Down; U.S. Stocks Mixed

Midday Report: Valeant Sinks as Deal Talks Break Down; U.S. Stocks Mixed

U.S. stocks held mixed as a rally in crude oil failed to provide an across-the-board lift.

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks turn mixed Wednesday as a rally in crude oil fails to provide an across-the-board lift.

Valeant Plummets on Reports of Salix Takeover Breakdown

Valeant Plummets on Reports of Salix Takeover Breakdown

Valeant shares fell Wednesday on news that talks with Takeda to take over Valeant's Salix unit have broken down.

Turnaround Stocks That Look Set to Bounce Back in 2017 or 2018

Turnaround Stocks That Look Set to Bounce Back in 2017 or 2018

CNBC's Mike Santoli examined some battered sectors that are not participating in the Trump rally, and which could be poised for a turnaround.

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about how Apple is still a short for him and that the market is still resistant.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

Allergan, Apple and Cisco: Doug Kass' Views

Allergan, Apple and Cisco: Doug Kass' Views

Doug Kass shares his thoughts on considering the contrary and shorting the Cisco Kid.

Wall Street Edges Higher as December Rate Hike Becomes More Certain

Wall Street Edges Higher as December Rate Hike Becomes More Certain

Wall Street moves higher on Thursday as investors grow more certain of a rate hike when Federal Reserve members meet in December.

Valeant and Philidor Execs Were Building 'Nest Eggs' from Valeant Stakeholders' Money, Bharara Says

Valeant and Philidor Execs Were Building 'Nest Eggs' from Valeant Stakeholders' Money, Bharara Says

The U.S. Department of Justice announced charges against former Valeant VRX executive for engaging in "a multi-million dollar fraud and kickback scheme."

Dow Off Highs as Crude Oil Makes Turn Lower

Dow Off Highs as Crude Oil Makes Turn Lower

Wall Street makes gains across all sectors on Thursday as investors trade on renewed certainty over a December rate hike.

Valeant (VRX) 'Ripped Off Pretty Hard' by Own People

Valeant (VRX) 'Ripped Off Pretty Hard' by Own People

Federal prosecutors in NY charged a former top executive at Valeant (VRX) and the ex-CEO of Philidor in a multimillion dollar kickback scheme.

Midday Report: Charges For Valeant Execs; S&P 500 Extend Gains

Midday Report: Charges For Valeant Execs; S&P 500 Extend Gains

The S&P 500 extended gains after comments from Federal Reserve Chair Janet Yellen reinforced the chances of a rate hike in December.

Stocks Mixed as Yellen Says Rate Hike Could Come Soon

Stocks Mixed as Yellen Says Rate Hike Could Come Soon

Stocks are mixed Thursday after Federal Reserve Chair Janet Yellen says that an interest rate hike could come soon.

Valeant and Philidor Execs Face Fraud Charges

Valeant and Philidor Execs Face Fraud Charges

The U.S. Department of Justice is set to announce charges against Valeant Pharmaceuticals executives for engaging in 'a multi-million dollar fraud and kickback scheme.'

Andrew Left: Dump Mallinckrodt

Andrew Left: Dump Mallinckrodt

Famed short-seller says drugmaker at risk of a government crackdown.

ESG Investing All About Making Money While Doing Good

ESG Investing All About Making Money While Doing Good

There is more to environmental, social and governance (ESG) investing than simply feeling good. There is also money to be made.

Allergan, Macy's, Apple: Doug Kass' Views

Allergan, Macy's, Apple: Doug Kass' Views

Doug Kass shares his thoughts on closed-end municipal bond funds.